SCHEMBL7126414

SCHEMBL7126414

CCOC(=O)c1cccc(Oc2ccccc2N)c1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.60
HSD17B10 Q99714 7/20 0.60
TSHR P16473 2/20 0.51
CDC25B P30305 3/20 0.49
HPGD P15428 6/20 0.46
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
MAPT P10636 3/20 0.46
GAA P10253 1/20 0.46
ALOX15 P16050 1/20 0.46
NPC1 O15118 4/20 0.43
KDM4E B2RXH2 3/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
POLB P06746 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31121003 0.88 TSHR (0.54) ALDH1A1HSD17B10TSHRCDC25BHPGD
SCHEMBL1096259 0.85 HTT (0.57) ALDH1A1HSD17B10TSHRCDC25BHPGD
SCHEMBL1097707 0.84 ALDH1A1 (0.68) ALDH1A1HSD17B10TSHRCDC25BHPGD
SCHEMBL7117324 0.80 ALDH1A1 (0.52) ALDH1A1TSHRCDC25BHPGDRAB9A
SCHEMBL11521675 0.80 TSHR (0.68) ALDH1A1HSD17B10TSHRCDC25BHPGD
SCHEMBL2894636 0.78 ALDH1A1 (0.72) ALDH1A1HSD17B10TSHRCDC25BHPGD
Ethyl Anthranilate SCHEMBL7560547 0.78 ALDH1A1 (0.96) ALDH1A1HSD17B10TSHRCDC25BHPGD
SCHEMBL7617766 0.78 ALDH1A1 (0.58) ALDH1A1HSD17B10TSHRCDC25BHPGD
SCHEMBL1097553 0.77 PPIA (0.56) ALDH1A1TSHRCDC25BSMN1; SMN2MAPT
Ethyl Anthranilate SCHEMBL27460908 0.77 ALDH1A1 (0.87) ALDH1A1HSD17B10TSHRCDC25BHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
US-6590118-B1 Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) NOVO NORDISK A/S (DK) 2003-07-08 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM ALDH1A1 901/4885HSD17B10 363/4885TSHR 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.